Drug Trial Radar · NCT04908865
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Oct 21, 2021
Primary completion
May 23, 2024
Study completion Aug 13, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the safety, efficacy and pharmacokinetics of belimumab administered in combination with background standard therapy in pediatric participants with active SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
BelimumabDrug
Belimumab will be administered.
Standard therapyDrug
Standard therapy will be continued.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52Time frame: Up to Week 52
- Number of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) ScoreTime frame: Baseline (Day 0) and Week 52
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Beijing, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Changsha, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Hangzhou, China
GSK Investigational Site
Nanjing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Suzhou, China
GSK Investigational Site
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.